

## STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER: STENO

### Interim Report Third Quarter 2020

STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2020 – 30.09.2020. The report is available on <https://stenocare.com/investor-relations/>

**Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:**

*“Despite significant challenges for society and businesses caused by the Covid-19 pandemic, the third quarter offered good progress for our business. We have been very busy executing our ambitious STENOCARE 2.0 strategy and look forward to continuing our progress in the final quarter of the year.”*

(DKKK)	01.07.2020 30.09.2020 3 months	01.07.2019 30.09.2019 3 months	01.01.2020 30.09.2020 9 months	01.01.2019 30.09.2019 9 months	01.01.2019 31.12.2019 12 months
Total income *)	0	0	93	4,942	16,206
Net sales	0	0	93	4,942	4,942
Operating profit before depreciation (EBITDA)	-2,492	-3,557	-7,985	-3,846	4,417
Net financial items	-134	-675	-1,637	-676	-2,112
Result per share (DKK)	-0.19	-0.37	-0.77	-0.40	0.19
Solidity (%)	98	46	98	46	43

Result per share: The result for the period divided by the average number of shares. Total number of shares as of September 30, 2020, amounted to 11,676,126 (8,942,762). Average number of shares for the third quarter 2020 was 11,676,126 (8,942,762).

Solidity: Equity divided by total capital.

\*Total income incl. net sales and other income.

#### Highlights during the period

- August 2020, STENOCARE announced that the Company’s shares have been included on the BSRM segment of the Börse Berlin under the code number A2N6HF.
- August 2020, STENOCARE published its interim report for the second quarter and first half-year of 2020. The interim report is available on the Company’s website ([www.stenocare.com](http://www.stenocare.com))
- September 2020, the Company announced its expectations on supplying medical cannabis oil products to Swedish patients during 2020, through their Canadian supplier Emerald Health Therapeutics Inc.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: [presse@stenocare.com](mailto:presse@stenocare.com)

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on November 05, 2020.

STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: [info@keswickglobal.com](mailto:info@keswickglobal.com)

#### About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency’s permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

[www.stenocare.dk](http://www.stenocare.dk) [www.stenocare.com](http://www.stenocare.com) [www.stenocare.se](http://www.stenocare.se)